Jurkat In Vitro Metaphase Chromosome Analysis Assay

CAT#: ITS-1122-YF5751
Target Cell Organism: Human
Target Cell Name: Jurkat
Assay Type: Genome Alteration Assays
Assay Overview
This assay is to provide Jurkat-based In Vitro Metaphase Chromosome Analysis Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.
Target Cell Name
Jurkat
Target Cell Organism
Human
Target Cell Background
The Jurkat cell line (originally called JM) was established in the mid-1970s from the peripheral blood of a 14-year-old boy with T cell leukemia. Different derivatives of the Jurkat cell line have been mutated to lack certain genes.
Related Diseases
Acute Lymphoblastic Leukemia; ALL
Research Area
Oncology
Assay Name
In Vitro Metaphase Chromosome Analysis Assay
Short Description
Jurkat-cell based In Vitro Metaphase Chromosome Analysis Assay
Assay Description
Metaphase chromosome analysis has become one of the main important tools in cancer genetics. As metaphase chromosomes are highly condensed and coiled, they are more appropriate for banding analysis and to subject for karyotyping.
Assay Type
Genome Alteration Assays
Assay Type Details
Aberrant or somatic mutations are more commonly found in the DNA of cancer cells compared to normal cells. There is an equilibrium that exists between DNA damage and repair in normal cells. However, in cancer cells these events are disturbed, resulting in mutations and genomic instability. Genomic instability in cancer cells causes chromosomal aberrations, microsatellite instability, aneuploidy and uncontrolled gene amplifications and genetic instability in cancer cells are mainly due to point mutations or chromosomal aberrations such as insertions, deletions and translocation, resulting in mutated proteins.
For Research Use Only | Not For Clinical Use
Online Inquiry